Change Location × Madrid

    Recent Locations

      2nd World Congress on COPD, Asthma and Lung Health in Madrid


      • 2nd World Congress on COPD, Asthma and Lung Health Photo #1
      1 of 1
      October 10, 2019

      Thursday   8:00 AM - 5:00 PM (daily for 2 times)

      7 Ronda de Valencia
      Madrid, Spain 28012

      Performers:
      • No Performers Listed
      EVENT DETAILS
      2nd World Congress on COPD, Asthma and Lung Health

      2nd World Congress on COPD, Asthma and Lung Health
      About this Event
      About

      Pulsus Group invites all the participants from across the World to attend “2nd World Congress on COPD, Asthma and Lung Health” during October 07-08, 2019 at Madrid, Spain. This includes proficient keynote presentations, verbal speeches, productive poster presentations and exhibitions.

      Pulsus Group performs 1000+ Global events annually, is delighted to welcome all the interested and enthusiastic participants across the globe to the prestigious Conference on “2nd World Congress on COPD, Asthma and Lung Health” during October 09-10, 2019 at Madrid, Spain. Lung Health 2019 highlights the theme “Frontiers in Lung Health Research”.

      Pulmonologists face a wide variety of challenges: Chronic Obstructive Pulmonary Disease (COPD) is an umbrella term used to describe progressive lung diseases including Asthma, emphysema, chronic bronchitis, and some forms of bronchiectasis. The lack of comprehensive information about the disease people with COPD typically ranges from 40% to 70%, depends on disease severity, while the 2-year mortality rate for people with severe COPD is about 50%. Survival rates for people with severe COPD are, in fact, worse than those for people with many common cancers. The COPD Foundation was established to undertake initiatives that result in expanded services for COPD and to improve the lives of individuals affected by COPD. The Foundation’s activities focus on achieving these results through research, education and advocacy programs that will lead to prevention and a cure for this disease.

      Designation Statement

      Pulsus Group is a Medical publisher that binds to stringent peer-review procedure with a view to set an example in enlightening standard medical research with integrity and attentiveness, established in 1984 with many offices in Singapore, Ontario, Canada and India. Pulsus Group takes dignity in assimilating the endorsements of prestigious associations and societies like Canadian Medical Societies, International Medical Societies. As a fervent supporter of medical publishing to expand its open access publishing through its 50+ journals in association with 20+ International medical and scientific societies. It publishes an extensive range of Medical Journals that focus on medical specializations like Cardiology, integrative medicine, surgery and reproductive medicine. Pulsus Group is closely associated with globally renowned academic and research societies like Canadian Transplant Society, Canadian Society of Plastic Surgeons, Canadian Society for Aesthetic Plastic Surgery, Group pours Canada, Canadian Society for Surgery of the Hand.

      Pulsus Group performs 1000+ Global events annually, is delighted to welcome all the interested and enthusiastic participants across the globe to the prestigious Conference on “Lung Health 2019” going to held during October 07-08, 2019 at Madrid, Spain.Lung Health 2019 highlights the theme “Frontiers in Lung Health Research”.

      Who should attend ?

      • Pulmonology Students, Scientists and Professors

      • Pulmonology Researchers

      • Pulmonology Faculty

      • Healthcare Students, Scientists and professors

      • Health Care Researchers

      • Healthcare Faculty and Equipment Management

      • Medical Colleges

      • Healthcare Associations and Societies

      • Business Entrepreneurs

      Why to Attend ?

      The Lung Health 2019 will provide a good opportunity to learn more clinical information and also it will enlighten the world with recent advances in COPD, Asthma and other Lung Diseases and Pulmonology research and inculcate new ideas about healthy breathing. Moreover, this COPD Conferences provides the participants with a great networking with peers. Internationally prominent speakers, the novel techniques, and the modern updates in the lung research fields are the unique attributes of this conference. COPD Conferences, symposiums and Workshops provide a dedicated forum for the advancement, execution and exchange of information about Pulmonology and Lung Health.

      Scope and Importance

      Pneumonic health has a specific enthusiasm for the effect changes in respiratory care and the mindfulness is expanding each year, and subsequently, Lung Health 2019 energizes entries from scientists situated in USA, Europe and Asian nations.

      The test of the field is to assess flow promising intercessions thoroughly, address rising issues, for example, incorporating consistently expanding research discoveries and create inventive dispersal and correspondence procedures.

      The diary welcomes entries on exploring in COPD, Asthma, tuberculosis, including emphysema, aspiratory recovery, cystic fibrosis, various pulmonary disease and themes identified with respiratory wellbeing.

      Lung Health 2019 provides a stage that encourages creators to impart their insight into a more extensive group of onlookers and supports a quick procedure for entries bringing about excellent distributions. We additionally mean to contribute towards lessening the disparity in distributions from low-and centre wage nations. Our group of onlookers is worldwide, and we mean to share explore brings about COPD from all parts of the world.

      Scientific Sessions

      Session 01: Lung Disease

      Lung diseases disorders or infections that affect the lungs and cause breathing problems. Some can lead to respiratory failure. The term lung disease refers to many disorders affecting the lungs, such as asthma, COPD, infections like influenza, pneumonia and tuberculosis, lung cancer, and many other breathing problems. Some lung diseases can lead to respiratory failure. Altogether, lung diseases accounted for more than 3 million people die each year from COPD and 235 million people suffer from asthma, a common disease among children.

      Session 02: Chronic Obstructive Pulmonary Disease

      Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. Symptoms include breathing difficulty, cough, mucus production and wheezing. It's caused by long-term exposure to irritating gases or particulate matter, most often from cigarette smoke. People with COPD are at increased risk of developing heart disease, lung cancer and a variety of other conditions. Emphysema and chronic bronchitis are the two most common conditions that contribute to COPD. The inflamed bronchial tubes produce a lot of mucus. This leads to coughing and difficulty breathing. It's characterized by a daily cough and mucus production.

      Session 03: Asthma and COPD

      Asthma is one of the chronic disease involving the airway in the lungs. This airway is called bronchial tubes, allow air to come in and out of the lungs. In this asthma your airway gets, and it will produce extra mucus. So that it can make breathing difficult and trigger coughing, wheezing and shortness of breath. It can be a major problem that interferes with daily activities and may lead to a life-threatening asthma attack. Asthma can't be cured, but its symptoms can be controlled. Because asthma often changes over time, it's important that we need to track our signs and symptoms and adjust treatment as needed. Asthma causes difficulty in breathing that often results from an allergic reaction. When it comes to COPD both are chronic inflammatory diseases that include the little airway routes and cause airflow impediment, both from communications and both are typically characterized by mucus and bronchoconstriction.

      Session 04: Lung cancer

      Lung cancer is a type of cancer that begins in the lungs and the uncontrolled growth of abnormal cells in one or both lungs. Your lungs are two spongy organs in your chest that take in oxygen when you inhale and release carbon dioxide when you exhale. Once the tumours have become larger and increased in number, they make it difficult for the lungs to provide oxygen to the bloodstream. People who smoke have the greatest risk of lung cancer, though lung cancer can also occur in people who have never smoked. The risk of lung cancer increases with the length of time and the number of cigarettes you've smoked. These cells usually line the air passages and divide rapidly to form tumours.

      Session 05: Tuberculosis

      Tuberculosis (TB) is caused by bacteria (Mycobacterium tuberculosis) that most often affect the lungs. Tuberculosis is curable and preventable is spread from person to person through the air. When people with lung TB cough, sneeze or spit, they propel the TB germs into the air. A person needs to inhale only a few of these germs to become infected. About one-quarter of the world's population has latent TB, which means people have been infected by TB bacteria but are not (yet) ill with the disease and cannot transmit the disease. One of the most commonly used vaccine for Tuberculosis infected patients especially for the infants is bacillus calmette guerin(BCG).

      Session 06: Idiopathic Pulmonary Fibrosis

      Idiopathic pulmonary fibrosis (IPF) is a type of lung disease that results in scarring fibrosis of the lungs for an unknown reason. Over time, the scarring gets worse and it becomes hard to take in a deep breath and the lungs cannot take in enough oxygen. IPF is a form of interstitial lung disease, primarily involving the interstitial the tissue and space around the air sacs of the lungs, and not directly affecting the airways or blood vessels. There are many other kinds of interstitial lung disease that can also cause inflammation and/or fibrosis, and these are treated differently.

      Session 07: Cystic Fibrosis

      Cystic fibrosis is an inherited disorder that causes severe damage to the lungs, digestive system and other organs in the body. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. These secreted fluids are normally thin and slippery. But in people with cystic fibrosis, a defective gene causes the secretions to become sticky and thick. Instead of acting as a lubricant, the secretions plug up tubes, ducts and passageways, especially in the lungs and pancreas.

      Session 08: Stages of Asthma

      Stage-1 or intermittent asthma: This group of children has symptoms no more than two times a week, do not have problems in-between flare-ups, and only have short flare-ups from a few hours to a few days. Night-time symptoms occur less than two times a month.

      Stage 2 or mild persistent: This group of children has symptoms more than two times a week, but not daily, and may have activity levels affected by the flare-ups. Night-time symptoms occur greater than two times a month, but no more than once per week.

      Stage 3 or moderate persistent: This group of children has symptoms every day, use their rescue medication every day and may have activity levels affected by the flare-ups. Night-time symptoms occur greater than one time a week.

      Stage 4 or severe persistent: This group of children has symptoms multiple times per day, have a decrease in their physical activity and have frequent flare-ups. Night-time symptoms occur frequently.

      Session 09: Asthma Immunopathology

      Bronchial asthma is a resistant interceded issue described by reversible aviation route irritation, mucous discharge, and a variable stream of air deterring with aviation route hyperresponsiveness. Allergen presentation prompts the initiation of different cells of the framework, of those dendritic cells and Th2 lymphocytes are of principal significance. Even though the epithelium was at first considered to work independently as a physical boundary, it is as of now detectable that it assumes a focal part in the Th2-cell refinement process because of its possibility to initiate dendritic cells. Pole cells and eosinophil were at first accepted to assume a key part in driving the aviation route irritation related to asthma, new information infer that T partner cells are basic. It has been demonstrated that hypersensitive asthma is related with expanded TH2 cytokine generation that causes initiation of eosinophils and T-cells and creation of chemokine by aspiratory fibroblasts.

      Session 10: COPD Pathogenesis

      Pathogenesis of chronic obstructive pulmonary disease is that chronic airflow limitation results from an abnormal inflammatory response to inhaled particles and gases in the lung. Basically, it has characterized, inflammation in the peripheral air spaces in different stages of disease severity. The first is a Protease-Antiprotease imbalance, which has been linked to the pathogenesis of emphysema. The second process, oxidative stress, has a role in many of the pathogenic processes of chronic obstructive pulmonary disease and may be one mechanism that enhances the inflammatory response.

      Session 11: Epidemiology of COPD

      Chronic obstructive pulmonary disease (COPD) is responsible for early mortality, high death rates and significant cost to health systems. Active smoking remains the main risk factor, but other factors are becoming better known, such as occupational factors, infections and the role of air pollution. Prevalence of COPD varies according to the country, age and sex. This disease is also associated with significant comorbidities. COPD is a disorder that includes various phenotype, the continuum of which remains under debate. The major challenge in the coming years will be to prevent the onset of smoking along with early detection of the disease in the general population. This may represent deterioration in the patient's premorbid condition such that hypoxemia worsens and hypercapnia develops during a relatively trivial respiratory tract infection, which may be viral or bacteria.

      Session 12:Cardiovascular Diseases and COPD

      Numerous cohort studies have demonstrated an increased risk of cardiovascular-related mortality in patients with COPD. Interestingly, this association is often seen in mild and moderate COPD. It is both disappointing and depressing that both the management of cardiovascular disease and the assessment of risk in patients with COPD is repeatedly suboptimal. The amino acids desmosine and isodesmosine are involved in elastin cross-linking, have utility as a measure of elastin breakdown, and may have value in determining both risk of cardiovascular disease and a link to a possible causal mechanism. The detection of increased arterial stiffness in patients with COPD furthers leads to the understanding of the possible mechanism for cardiovascular disease in COPD.

      Session 13: Respiratory Failure and COPD Complications

      Patients who struggle with advanced COPD and acute or chronic respiratory failure are at high risk of death. Beyond pharmacological treatment, supplemental oxygen and mechanical ventilation are major treatment options. If your lungs fail to do their job passing oxygen into your bloodstream and removing carbon dioxide. It can be a complication of chronic obstructive pulmonary disease (COPD). In respiratory failure, the gas exchange doesn't work the way it's supposed to work, and the cells in your body start to suffer from a lack of oxygen, too much carbon dioxide, or both. Too much carbon dioxide can disrupt the acid-base balance in the body, which in itself can lead to respiratory failure.

      Session 14: Pathophysiology of COPD

      Basically, the pathophysiology of COPD is rapidly unveiling. There will be some physiological change which eventually impacts the quality of life and survival in the natural progress of COPD when The pathological consequences of the COPD inflammation induce a series of physiological changes. Fibrotic remodelling of the airways results in fixed airway narrowing causing increased airway resistance which does not fully revert even with bronchodilators. Emphysema also reduces lung elastic recoil pressure which leads to a reduced driving pressure for expiratory flow through narrowed and poorly supported airways in which airflow resistance is significantly increased.

      Session 15: Pulmonary Diseases-Treatment and Therapies

      Treatment is depending upon the type of disease and stages. Either it will be treated in the surgical or non-surgical method, when it comes to the surgical process some of the treatments are lung transplant, Lung volume reduction surgery and Bullectomy, another type is known a non-surgical process here, Airway clearance therapy, Pulmonary Rehabilitation, Vaccines, and antibiotics.

      Session 16: Self-Management and Prevention of COPD

      Patients with Chronic Obstructive Pulmonary Disease have to acquire and the skills they need to carry out disease, Self-management in chronic obstructive pulmonary disease, centring on an action plan for the exacerbation and enhanced communication between the patient and healthcare providers, make good clinical sense. only two demonstrated reductions in health care utilization and one had to be discontinued prematurely because of increased mortality. Breathing techniques that can help you get the air you need without working so hard to breathe, Our primary objective was to assess the long-term effects of two different modes of COPD disease management comprehensive self-management and routine monitoring on quality of life in COPD patients in general practice. As secondary objectives, we assessed the effects on frequency and patients’ management of exacerbations and on self-efficacy. A systematic review of self-management in COPD concluded that it reduces hospital admissions and has no detrimental effects.

      Session 17: Advanced Respiratory Disease Treatment

      Nowadays patients with Respiratory diseases use various devices, which help the removal of mucus from the Airways and the improvement of pulmonary function.Pulmonary Rehabilitation helps in recovering the normal lung expiration and inspiration through trainings and exercises. Other Advanced treatment methods are Bullectomy and Bronchoscopic lung volume surgery where the idea is to provide a free air pathway without any resistance. Nowadays devices seem to increase patients' compliance with daily treatment, because they present many benefits, as an independent application, full control of therapy and easy use.

      Session 18: Paediatric Pulmonary Critical care and Sleep

      The Division of Paediatric Pulmonary and Sleep Medicine provides comprehensive care to infants, children and adults with a full spectrum of respiratory disorders. Care is guided in all age groups by the routine measurements of lung function. This department also provides the teaching and training in paediatric Pulmonology for diagnosing and treating the various disorders. mostly various pulmonary disorders are treated with the help of ventilation machines and medications.

      Session 19:Diagnosis for Pulmonary Disorders

      The most traditional method for diagnosing the pulmonary disorders is with the usage of the spirometer which generally provides measurement about the lung capacity and also about the inhalation and exhalation of air. By using spirometer it is also possible to tract the progression of the disease such as COPD and also early detection of the disease.

      Cost: $1,199 – $2,700

      Categories: Conferences & Tradeshows

      This event repeats daily for 2 times:

      Event details may change at any time, always check with the event organizer when planning to attend this event or purchase tickets.